MemTrax A game to measure memory and screen for memory impairment, particularly early Alzheimer’s disease J. Wesson Ashford, M.D., Ph.D. Clinical Professor.

Slides:



Advertisements
Similar presentations
Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which? Lockhart BP, Lestage PJ. January 2003.
Advertisements

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D1 – AD brain scans – perfusion SPECT NUCLEAR MEDICINE.
APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Speed of processing, the missing measure in early detection of MCI? Ruth O’Hara March 13 th 2001 Yogesh Shah.
Management of Early Dementia Dr Eleanor Mullan Consultant Psychiatrist Mental Health Services for Older People South Lee, Cork Feb 2011.
MemTrax (Computerized Memory Screen) American Association of Geriatric Psychiatry (AAGP) March 2, 2007 J. Wesson Ashford, M.D., Ph.D. Stanford / VA Aging.
Martha Stearn, MD Institute for Cognitive Health St John’s Medical Center Jackson, Wyoming.
Dementia and Aging Steven Huege, M.D Assistant Professor of Clinical Psychiatry Perelman School of Medicine at the University of Pennsylvania.
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
MCB 135K: Discussion March 2, General Info Mid-Term I: –Avg 87 –Std. Deviation 10 –Re-grades by next Wednesday Include a cover sheet that addresses.
Dementia & Delirium in Surgical Patients Damian Harding Department of Geriatric Medicine February 2008.
Aging of the Nervous System: Functional Changes P.S. Timiras.
Alzheimer’s Disease Nicotine’s relationship and contribution to dementia.
Alzheimer’s Disease Find group of ~4 students ~ 10 minutes Discuss the following personal family connection to AD (if willing only) observations/experiences.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
ACT on Alzheimer’s Disease Curriculum Module VI: Screening.
University of Kansas Medical Center
Dementia. Definition Loss of function in multiple cognitive abilities Assuming the individual had normal abilities before the onset Many of the 70 recognized.
PSYC D Dementias 1 Dementias. Dementias 2 Neurodegenerative Disorders A varied assortment of central nervous system disorders characterized by.
Aging, Memory and Alzheimer’s Disease Kinga Szigeti, MD, PhD.
Alzheimer’s Disease By: Ryan Triplett. Alzheimer’s The deterioration of intellectual capabilities, memory, judgment, and personality to the extent that.
Middle and Old Age. Maximum Recorded Life Spans Human Indian Elephant Gorilla Common Toad Domestic Cat Domestic Dog Vampire Bat House Mouse
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part A – AD definition, neuropath? NUCLEAR MEDICINE GRAND.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 22 Alzheimer’s Disease.
ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.
How Is Your Memory? Evaluating Memory in the Individual and Its Relationship to Alzheimer's Disease J. Wesson Ashford, M.D., Ph.D. Clinical Professor (affiliated)
Methodological Issues 4 Age effects - the consequence of being a given chronological age 4 Cohort effects - the consequences of having been born in a given.
Biological Myths of Aging Memory declines drastically with age for all people. IQ declines drastically with age in all people. Learning becomes more difficult.
ALZHEIMER’S DISEASE DIAGNOSIS and TREATMENT J. Wesson Ashford, M.D., Ph.D. Stanford / VA Alzheimer’s Center VAMC, Palo Alto, California Calabasas, California.
Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.
Stroke and Alzheimer’s Disease Dr Jackie Hunter Senior Vice-President Neurology & Gastrointestinal Centre of Excellence for Drug Discovery GSK Harlow.
Alzheimer’s Disease Causes, Effects, and Treatments.
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
Amnesia Syndromes Lesson 22. Wernicke-Korsakoff’s Syndrome n Deficits similar to H.M. l Anterograde l retrograde more severe n Cause: Long-term alcohol.
ALZHEIMER PATHOLOGY AND NEUROPLASTICITY AD ATTACKS NEUROPLASTIC MECHANISMS NEUROPLASTICITY AS THE FOCUS OF THE ALZHEMIER ATTACK ALZHEIMER ATTACK AS A MODEL.
Six Steps to a Better Brain Majid Fotuhi, MD PhD March 6, 2014.
NOW WHERE HAVE I PUT MY GLASSES? A DISCUSSION AROUND DEMENTIA Dr Marion Overton U3A SCIENCE 19TH JUNE 2015.
WHAT DO YOU REMEMBER ABOUT ALZHEIMER’S DEMENTIA?.
Introduction Alzheimer’s disease (AD) is a neurodegenerative disease associated with brain shrinkage and the loss of neurons, particularly cholinergic.
Using computers to conduct mass screening for dementia - practical issues and ethics - April 15, 2011 International Association of Geriatrics and Gerontology.
Alzheimer’s Disease By: Chelcy Branon. Facts  In 2006, there were 26.6 million sufferers worldwide  Costs 100 billion dollars per year.
1 Alzheimer’s Disease & Acetylcholine Presentation by: Huy Nguyen Chemistry 12B Instructor: Dr. Adamczeski Fall-2006.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part C – AD brain scans - anatomical NUCLEAR MEDICINE GRAND.
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
ALZHEIMER’S WHAT IS IT – WHAT TO DO ABOUT IT. VIDEO
Cognitive Disorders Chapter 13 Nature of Cognitive Disorders: An Overview Perspectives on Cognitive Disorders Cognitive processes such as learning, memory,
Dementia Nicholas Cascone, PA-C.
Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
Alzheimer’s disease.
It is a chronic neurodegenerating disease that usually starts slowly and gets worse over time.
Definition  Alzheimer's disease, it is a brain disorder, is most commonly to forget things&affects a person's ability to accomplish daily activities.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part B – AD and brain systems NUCLEAR MEDICINE GRAND ROUNDS.
ALZHEIMER’S DISEASE DIAGNOSIS and TREATMENT J. Wesson Ashford, M.D., Ph.D. Stanford / VA Alzheimer’s Center VAMC, Palo Alto, California October, 2004 Slides.
Alzheimer’s Disease: 진단과 치료
Types of Dementia Dr Bernie Coope Associate Medical Director/Honorary Senior Lecturer, Worcester University Association for Dementia Studies.
Chapter 14 Neurocognitive Disorders
Frontotemporal Lobar Degeneration:
DEGENERATIVE DISEASES is a disease in which the function or structure of the affected tissues or organs will progressively deteriorate over time, whether.
DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP. Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with.
Overview of Alzheimer’s Research
Memory Deficiency & Memory
Memory Deficiency & Memory
Aging in the CNS.
Amnesia Syndromes Lecture 21.
Dementia Supischa Theerasasawat Eric Pfeiffer, M.D J. Wesson Ashford
Chapter 30 Delirium and Dementia
Chapter 25 The Elderly.
Presentation transcript:

MemTrax A game to measure memory and screen for memory impairment, particularly early Alzheimer’s disease J. Wesson Ashford, M.D., Ph.D. Clinical Professor (affiliated), Department of Psychiatry and Behavioral Sciences Senior Research Scientist, Stanford / VA Aging Clinical Research Stanford University and VA Palo Alto Health Care System August 27-28, 2012 Slides at: www.medafile.com (Dr. Ashford’s lectures) MemTrax: www.memtrax.com ; www.memtrax.net ; www.memtrax.org

Episodic memory - Retentive memory Specifically, information that is perceived then retained after distraction Highly dependent on proper neuronal functioning of the medial temporal lobe of the brain

Alzheimer pathology affects regions of the cortex that have a high capacity and responsibility for memory storage Sensory, Perception, Memory systems of cortex – Ashford, Coburn, Fuster, 1998

Episodic memory Disrupted by diseases that affect the medial temporal lobe: Hypoxia Ischemia (including vascular dementia), Hypoglycemia, Thiamine deficiency, Alzheimer’s disease (AD), which devastates this area early in it course

Dementia Definition Multiple Cognitive Deficits: Memory dysfunction especially new learning, a prominent early symptom At least one additional cognitive deficit aphasia, apraxia, agnosia, or executive dysfunction Cognitive Disturbances: Sufficiently severe to cause impairment of occupational or social functioning and Must represent a decline from a previous level of functioning

Discrete regions of the cerebral cortex are selectively affected by Alzheimer pathology Brun & Englund, 1986

Braak & Braak, 1991; Braak et al., 2006

Correlation analysis between brain perfusion (SPECT) and dementia severity (transformed from the MMSE) (Ashford et al., 2000). This finding is consistent with observations using numerous other modalities, e.g, PET Correlation Proportion of cortical area

Cholinergic Changes in AD - 1976 The most prominent neurotransmitter abnormalities in AD are cholinergic Reduced activity of choline acetyltransferase (synthesis of acetylcholine)1 Reduced number of cholinergic neurons in late AD (particularly in basal forebrain)2 Selective loss of nicotinic receptor subtypes in hippocampus and cortex1,3 The associated decline of cognitive function in AD with decreased cholinergic neurotransmission in the cortex, hippocampus, and amygdala is the basis for what is known as the cholinergic hypothesis of AD 1. Bartus RT et al. Science. 1982;217:408-414. 2. Whitehouse PJ et al. Science. 1982;215:1237-1239. 3. Guan ZZ et al. J Neurochem. 2000;74:237-243.

Cholineric Hypothesis of AD Anti-muscarinic agents cause memory impairment – similar to AD Cholinergic agents improve memory function Acetyl-cholinesterase is decreased in the AD brain 1976 – 3 studies show decreased choline-acetyltransferase in AD brain 1981 - Loss of cholinergic neurons in nucleus basalis of Meynert in AD Cholinergic agents considered for treatment – lecithin, agonists Cholinesterase inhibitors (AChE ) considered for treatment of AD 1st double blind study - physostigmine - Ashford et al., 1981 1st successful treatment of AD - physostigmine - Thal et al., 1983 4 AChEI medications subsequently approved by FDA for treating AD AChEIs presumably increases acetylcholine at synapses Improvement in cognition (? 6-12 months better) Improvement in function (ADLs, variable) Improvement in behavior (? basal ganglia) Loss of nicotinic brain receptors is biggest chemical change in AD brain Slowing of disease course Treatment delays nursing home placement There is loss of benefit with delay of treatment May treat disease process, not just symptoms

Problems with the Cholinergic Hypothesis Many cholinergic neurons throughout brain, spinal cord, but only discrete groups of ACh neurons are affected in AD Numerous other neurotransmitter systems are affected in AD Cholinergic agents are only modestly effective in treating AD, slowing progression No clear relationship between acetylcholine and microscopic neuropathological features

Specific groups of cholinergic, serotonergic, and noradrenergic that project to the cortex, and glutamatergic and somatostatinergic GABA neurons of discrete cortical regions are selectively affected in Alzheimer’s disease Most affected) by AD -memory-write signal Cortex - Glutamate neurons - highly affected by AD - detail memory - Rx: memantine GABA neurons - Somatostatinergic neurons affected by AD – memory modulation Rx: cholinesterase inhibitors (not affected by AD - movement) (Affected by AD -operant conditioning) (Affected by AD early - Classical conditioning)

Anti-amyloid therapies No clear benefit from any therapies Flurbiprofen – hi-price failure Anti-bodies (do remove amyloid plaque) Some question of relation to APOE genotype Multi-billion dollar investments All studies of anti-Abeta rx have failed!!! Possible relationship to statins, NSAIDs No therapeutic benefit shown, so why would starting earlier have benefit??

Neuropil Thread Pathology, which Occurs in Dendrites, is Composed of Hyperphosphorylated TAU Protein and mabe Linked Back to Intact Neuronal Cell Bodies Through Intact Dendrites, though the Neuropil Threads Appear to be able to Break the Dendrites, presumably Amputating all Distal Synapses Shown on the next slides is a view which reflects observations from a double labeling (with PHF-1 and MAP-2) analysis of neurons in the cortex affected by Alzheimer’s disease (Ashford et al., 1998).

Double-immunolabeling of posterior cingulate neurons for: PHF-1 (brown stain) and MAP2 (pink-purple stain) A to L are from AD cases. J is stained only for MAP2. M is from a nondemented elderly. See: http://www.medafile.com/jwa/JWA98npt.pdf

Progression of tau hyperphosphorylation to neuropil threads and neurofibrillary tangles Ashford et al., 1998, J Neuropathol Exp Neurol.57:972

Stimulated by acetylcholine through muscarinic receptor intracellular extra cellular APP – formed during learning - XS in Downs Lipid raft Formed by cholesterol -Transported by ApoE (from macroglia) Iceland mutation APP-673 – no AD Stimulated by acetylcholine through muscarinic receptor Pathway to build new synapses Pathway to remove old synapses NEXIN Stimulates new synapse growth Amyloid –beta: ? Free-radical generator ? To destroy old synapses Turn-over – 8 hours Clearance – IDE, APOE AICD Favored when lipid raft too thick JW Ashford, MD PhD, 2012

Alzheimer Neuroplasticity Cascade Hypothesis Genetic Factors – all related to APP SNPs - related to APP/beta (strongest factors, but rare) APOE genotype – related to APP management (most common) APP 50% excess – Down Syndrome APP cleavage control (neuroplasticity – APP switch) Alpha stimulation failure (chemical causes, inadequate stimulation) Beta degradation over-activity (caused by stress, excess new information) AICD - APP-intracellular domain Stimulates tau-hyperphosphorylation causing synapse retraction, forgetting Gamma secretase modulation prevents AD (NSAIDs, statins) Excess AICD causes Tau hyperphosphorylation – pTau, poor synapse formation Poor synapse formation leads to memory failure Excess pTau causes Paired helical filament (PHF) formation PHF aggregation leads to Neuropil Thread formation Neuropil threads cause dendritic amputation, breakage Dendritic amputation causes massive synapse loss and dementia Neuropil threads migrate back to cell body to cause tangles

Memory tests relevant to Alzheimer’s disease Memory Tests (examples of commonly used tests for assessing memory possibly related to dementia, see Larrabee & Curtiss, 1995): California Verbal Learning Test Hopkins Verbal Learning Test Buschke Selective Reminding Test Fuld Object Learning Test Rey Auditory Verbal Learning Test Benton Visual Retention Test Paired Associate Learning Brief Visuospatial Memory Test Rey-Osterreith Complex Figure (delayed recall) Wechsler Memory Scale Visual Paired Associates (with delayed test) Verbal Paired Associates (with delayed test) Paragraph recall

Computerized Cognitive/Memory Tests CANS-MCI - Alzheimer’s Screen Inc. - www.alzheimersscreen.com Hill, Emory - emory.hill@comcast.net Cognosis - Cantab www.cantab.com Cognitive Drug Research - CDR - www.cdr.org (Goring-on-Thames, UK) Wesnes, Keith - enquiries@cdr.org.uk Cognitive Screening Test – CST www.headminder.com CNS Vital Signs - www.cnsvs.com Boyd, Alan (CNS vital signs, NC, USA) - aboyd@cnsvs.com Cognometer - www.cognitivelabs.com Addicott, Michael Cognitive Labs - - Michael@cognitivelabs.com Cogstate - www.cogstate.com (Australia) Bick, Peter - PBick@cogstate.com Cognistat - www.cognistat.com Cognisyst - www.cognisyst.com (Durham, NC) Green, Paul; Allen, Lyle - research@cognisyst.com Cog Screen - www.cogscreen.com Kay, Gary - gkay@tidalwave.net CogTest - www.cogtest.com Sharma, Tonmoy - info@cogtest.com IntegNeuro Paul et al., 2005 Medical Care Corporation - www.mccare.com Shankle, William Rodman - rshankle@mccare.com - see on-line test: www.mccare.com/content/mcis/mcis_overview.html Medical Decision Logic, Inc Tien, Allen - allen@mdlogix.com Memtrax www.memtrax.com /.net /.org Ashford, J. Wesson - washford@medafile.com MicroCog Elwood, 2001 Powell, DH; Kaplan, EF, Whitla D, Weintraub S, Catlin R, Funkenstein HH NetMet - www.netneuromet.com Crooks, Thomas - info@netneuromet.com Neurotrax - www.neurotrax.com (MindStreams) Simon, Ely - info@neurotrax.com

Issues for Memory Screening Current testing for memory problems is based on having a tester sit in front of a subject for a prolonged period of time and administer unpleasant tests Testing must be Inexpensive (minimal need for administrator) Fun (so people will return for frequent testing) More precise, reliable, and valid To improve sensitivity To improve specificity

Need for Mass Screening Alzheimer’s disease, dementia, and memory problems are difficult to detect when they are mild about 90% missed early about 25% are still missed late There are important accommodations and interventions that should be made when there are cognitive impairments (like needing glasses or having driving restrictions if you have vision problems)

MemTrax Memory Screening Presentation of complex pictures (that are easily remembered normally) are useful for detecting memory difficulties Picture memory can be tested by computer, internet Continuous Recognition Testing (CRT) needs standardization for population use Picture memory is less affected by education Other types of stimuli – e.g., faces, figures, written words – symbolic vs. abstract – can be used Audiences can be shown slide presentations

MemTrax Memory GAME 1 50 pictures will be shown (usually there are 10 practice pictures that will be shown first, not now). When you see a picture for the first time, look at it carefully and try to remember it. If you recognize a picture that you have seen before, then respond as quickly as possible (tap space-bar)

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

MEMTRAX Memory Test - answers 116 subjects – mostly elderly normals, some young, some dementia patients False positive errors (false recognition) – 33(64);6(58);47(27)—4,18,23,34(1);1,2,8(0) False negative errors (failure to recognize) – 35(33);27(20);5(16)—32(4);24(3);45(3)

The relationship between discriminability (d′) and age on the audience-based continuous recognition test of memory for 868 individuals with all information available The relationship between discriminability (d′) and age on the audience-based continuous recognition test of memory. Each data point represents the recognition score of an individual participant expressed as a discriminability index d′. One individual whose score was unusually poor (d’ = -2.64) was removed from the plot. Ashford, Gere, Bayley, Journal of Alzheimer’s Disease, 2011 44

The relationship between discriminability performance (d′) and age in 868 individuals on the continuous recognition test of memory - Showing Standard Errors of the Mean The relationship between discriminability performance (d′) and age in 868 individuals on the continuous recognition test of memory. Numbers inside the bars indicate the group n. The bars show the mean discriminability score for each age group and brackets show SEM. Ashford, Gere, Bayley, JAD, 2011 45

The relationship between discriminability performance (d′) and age in 868 individuals on the continuous recognition test of memory – Showing Standard Deviations The relationship between discriminability performance (d′) and age in 868 individuals on the continuous recognition test of memory. Numbers inside the bars indicate the group n. The bars show the mean discriminability score for each age group and brackets show one standard deviation on either side of the mean. Ashford, Gere, Bayley, JAD, 2011 46

The relationship between discriminability index (d′) and education in 868 individuals on the continuous recognition test of memory Numbers inside the bars indicate the group n. The bars show the mean discriminability score for each age group and brackets show SEM. Ashford, Gere, Bayley, JAD, 2011 47

WEB-based Screening On-line Testing Same test paradigm as Audience Screening Testing can be faster – 1-2 minutes for 50 images Many different variations of the test can be given Other aspects of cognition can be tested Test can be repeated frequently to decrease variance Test can be taken over time to detect changes Improved anonymity to protect private information

Screening Tests Available On-Line www.memtrax.com (clinical) www.memtrax.net (games) www.memtrax.org (research www.medafile.com (information) Slides at: www.medafile.com For further information, contact: Wes Ashford: washford@medafile.com